Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Clofazimine · Lamprene, G-30320

Small molecule · developed by Novartis

Approved FDA, Dec 1986
1 Registered trials

What is Clofazimine?

Clofazimine is an antimycobacterial drug.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Lamprene, G-30320, NSC-141046
Drug type
Small molecule
Therapy area
Infectious disease, Respiratory
Developer
Novartis
In trials of
MNKD
FDA status
Approved as Lamprene (December 15, 1986), NDA019500 · FDA label
UNII
D959AE5USF

✅ FDA-approved uses

From the indications section of the FDA label (version of Aug 17, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06418711 Phase 3 MAC Lung Disease Terminated MNKD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

MAC Lung DiseaseMycobacterium Infections, NontuberculousTreatment Refractory MAC Lung Disease

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.